Travere Therapeutics (TVTX) Cash from Investing Activities Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 116.52% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.24% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -22.09% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 30.54% |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | 37.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.19% |
| Dec 31, 2025 | -41.89% |
| Sep 30, 2025 | 104.81% |
| Jun 30, 2025 | 28.54% |
| Mar 31, 2025 | 7.58% |
| Dec 31, 2024 | -134.51% |
| Sep 30, 2024 | 12.36% |
| Jun 30, 2024 | 33.86% |
| Mar 31, 2024 | 44.10% |
| Dec 31, 2023 | -21.36% |
| Sep 30, 2023 | 72.00% |
| Jun 30, 2023 | -32.90% |
| Mar 31, 2023 | -43.20% |
| Dec 31, 2022 | -193.29% |
| Sep 30, 2022 | 31.18% |
| Jun 30, 2022 | -52.54% |
| Mar 31, 2022 | 69.92% |
| Dec 31, 2021 | 29.09% |
| Sep 30, 2021 | 30.08% |
| Jun 30, 2021 | -65.99% |
| Mar 31, 2021 | -71.79% |
| Dec 31, 2020 | -968.11% |
| Sep 30, 2020 | -170.21% |
| Jun 30, 2020 | 15.71% |
| Mar 31, 2020 | 112.44% |
| Dec 31, 2019 | -62.71% |
| Sep 30, 2019 | 39.89% |
| Jun 30, 2019 | 98.98% |
| Mar 31, 2019 | -5.37% |
| Dec 31, 2018 | 21.39% |
| Sep 30, 2018 | -72.06% |
| Jun 30, 2018 | 171.30% |
| Mar 31, 2018 | 12.20% |
| Dec 31, 2017 | -27.08% |
| Sep 30, 2017 | -1.98% |
| Jun 30, 2017 | 109.74% |
| Mar 31, 2017 | 28.72% |
| Dec 31, 2016 | 188.84% |
| Mar 31, 2016 | -95.44% |